|
|
||||||||
J Thorac Cardiovasc Surg 1999;118:815-822
© 1999 Mosby, Inc.
SURGERY FOR ACQUIRED CARDIOVASCULAR DISEASE |
From the Division of Cardiac Surgery, Brigham and Womens Hospital,a and the Neuroepidemiology Unit, Boston Childrens Hospital,b Harvard Medical School, Boston, Mass.
*Dr Chen is an American College of Surgeons Research Scholar 1998-2000 and recipient of a National Institutes of Health Individual National Research Service Award (NRSA) 1F32HL0996601.
Address for reprints: David H. Adams, MD, Cardiac Surgery, Brigham and Womens Hospital, 15 Francis St, Boston, MA 02115 dhadams{at}bics.bwh.harvard.edu).
| Abstract |
|---|
|
|
|---|
21-mm valves (P
.0005). The univariable odds ratio for operative death for 19-mm versus
21-mm valves was 6.4 (95% CI 2.7, 15.4; P
.0005). In the final multivariable model, receipt of a 19-mm valve alone was not a statistically significant predictor of operative death (odds ratio 2.1; 95% CI 0.7, 6.4; P = .21). However, the combination of male sex and 19-mm valve resulted in a significant risk of operative death (4/9 patients; odds ratio 17.5; 95% CI 2.2, 139; P = .007). Use of a 19-mm valve was not related to late death in either the univariable (hazard ratio 1.0; 95% CI 0.5, 2.0; P = .95) or the multivariable analysis (hazard ratio 0.7; 95% CI 0.3, 1.8; P = .51). | Introduction |
|---|
|
|
|---|
| Patients and methods |
|---|
|
|
|---|
Patient characteristics were defined as follows. Body surface area (BSA) is body morphometric analysis indexing weights and heights. Diabetes mellitus indicates a history of diabetes, regardless of duration of disease or need for antidiabetic agents. Renal failure is defined as a documented fasting serum creatinine level of 2.0 mg/dL. Stroke refers to a central neurologic deficit that is unresolved at the time of primary hospital discharge. COPD is defined as the need for pharmacologic therapy for chronic pulmonary compromise or as a forced expiratory volume in 1 second of less than 75% of predicted value. Ejection fraction is defined either by the catheterization report or cardiac echocardiogram. Myocardial infarction is defined either as the appearance of a new Q wave in 2 or more contiguous leads on the electrocardiogram or as clinical, angiographic, electrocardiographic, and/or laboratory isoenzyme evidence of myocardial necrosis if the electrocardiogram shows no new Q waves. Congestive heart failure has to fulfill at least 3 of the following criteria: presence of dyspnea, râles thought to represent pulmonary congestion, peripheral edema, cardiomegaly on chest x-ray film, and chest x-ray film compatible with interstitial edema. Reoperation includes patients who had any prior cardiac operations. Nonelective status describes an operation that is required during the same admission because of instability. Severe aortic stenosis designates all cases reported as "severe" by either preoperative catheterization or cardiac echocardiography. CABG denotes patients whose AVR operation was combined with concomitant CABG. Ischemic time (crossclamp time) is the total number of minutes the aorta is completely crossclamped during bypass. Operative death includes all deaths that occurred within 30 days of the AVR operation or death that occurred within the same admission. Cardiac cause of death includes the inability to wean from cardiopulmonary bypass, low cardiac output incompatible with life, life-threatening cardiac arrhythmia, and postoperative hemorrhage. Multiorgan system failure indicates compromised function of 2 or more major organ systems. Gastrointestinal etiology includes episodes of severe gastrointestinal hemorrhage or intestinal ischemia. Adult respiratory distress syndrome includes all patients with documented ARDS by clinical examination with or without a chest radiograph. Pneumonia describes positive sputum, blood, pleural fluid, empyema fluid, transtracheal fluid, or transthoracic fluid cultures consistent with the diagnosis and clinical finding of pneumonia or chest x-ray evidence of pulmonary infiltrates. Sepsis is defined as an active infection with positive blood culture. Atrial fibrillation indicates multiple atrial foci that discharge without a single uniform atrial depolarization documented by either monitor or electrocardiogram. Bleeding includes all patients who required surgical exploration, either in the operating room or in the intensive care unit, for postoperative continued hemorrhage. Ventilatory support is the number of postoperative days during which the patients required ventilatory support, which include days in which they are dependent at night or for periods during the day, but does not include oxygen support with a face mask. Intensive care unit stay refers to the number of days in the intensive care unit before the patient is moved to the step-down unit.
Statistical analysis.
This is an observational study and patients were not randomly assigned to receive valves of a particular size; valve size was the surgeons choice. Thus we evaluated the relationships between patient characteristics and size of the implanted valve so that we might control for the differences between the group receiving 19-mm valves and the group receiving
21-mm valves with a propensity score.
19,20 Univariable evaluations were made with Fishers exact test and the Wilcoxon rank-sum test. Characteristics considered in calculating the propensity score were age, BSA, diabetes, renal failure, hypertension, stroke, chronic obstructive pulmonary disease, ejection fraction, previous myocardial infarction, congestive heart failure, reoperation, nonelective procedure, presence of severe aortic stenosis, and concomitant CABG and Carpentier-Edwards valve. These risk factors were entered into a logistic regression model to predict receipt of a 19-mm valve. A parsimonious model was developed, interactions among variables in that model were examined, and finally risk factors not in the parsimonious model were added back to account, as much as possible, for all differences between the 2 groups. The propensity score, then, is the probability of receiving a 19-mm valve predicted by this final model. Patient sex was not used to calculate the propensity score because we wanted to evaluate the relationships between sex, valve size, and mortality. Multivariable logistic regression and multivariable proportional hazards regression were used to predict operative mortality and morbidity risk and hazard of late death, respectively, associated with small valve, patient sex, and the interaction between small valve and sex while controlling for patient differences via the propensity score. We performed multivariable logistic regression analyses, again using propensity scores, to predict operative mortality in strata of sex and valve size. We repeated our final multivariable logistic analysis 1000 times on samples of the same size as the total sample drawn randomly from the total sample (bootstrapping) to get a more conservative estimate of the effect of our interaction term. Statistical analyses were performed with the use of Stata version 6 software (Stata Corporation, College Station, Tex).
| Results |
|---|
|
|
|---|
|
.0005). In both groups, men had significantly larger BSAs. Median BSA for female patients (n = 186) was 1.69 m2 (IQR 1.56-1.80 m2) and for male patients (n = 180), 1.93 m2 (IQR 1.82-2.04 m2). Interestingly, 39 patients (38%) with a measured annular size appropriate for a size 19-mm prosthetic valve had a BSA of 1.7 m2 or more. Specifically, of all women who received a 19-mm valve, 34% (32/93 patients) had a BSA of 1.7 m2 or more. Among male patients who received a 19-mm valve, 78% (7/9 patients) had a BSA of 1.7 m2 or more.
Operative mortality.
Operative death was significantly more likely in women (72% vs 49%; P = .02), in older patients (median age 82 vs 77 years; P = .002), and in smaller patients (median BSA 1.69 vs 1.82 m2; P = .008)(Table II). Risk factors for operative mortality included diabetes mellitus, history of previous myocardial infarction, and urgent/emergency status. Patients receiving a 19-mm aortic valve prosthesis were also at significantly increased risk for operative mortality; 68% of operative deaths occurred in patients receiving 19-mm valves, whereas 25% of survivors received a 19-mm valve (P = .001). The most common cause of death was cardiac in origin in both groups(Table III).
|
|
21-mm valve (44% vs 2%; P
.0005). Thus we added a sexvalve size interaction term in our final multivariable analysis model(Table IV
2 = 7.2; df = 1; P = .007). The goodness-of-fit
2 (df = 8) yielded a P value of .40. In diagnostic plots, the men receiving small valves had fairly high leverage but were not among the observations with large Hosmer-Lemeshow
2 influence or
-D influence statistics.
|
|
We remained concerned that the malesmall valve interaction reflected valve mismatch. We fit a final model that included terms for BSA less than 1.7 m2 and interaction between small valve and BSA of 1.7 m2 or more to see whether these would displace the malesmall valve term(Table IV
, model 7). Men receiving small valves continued to be at significantly increased risk of operative death (OR 12.2; 95% CI 1.2, 122; P = .03). Both BSA terms had odds ratios of about 3. Although it did not reach statistical significance, there is the suggestion that valve mismatch may confer additional risk of operative death. However, this model really stretches the data; confidence intervals are large. In diagnostic plots, the men receiving small valves, however, had leverage similar to that in the earlier model, and the Hosmer-Lemeshow
2 influence and
-D influence statistics for other observations that were large before were still larger.
Morbidity.
Postoperative morbidity was evaluated in all patients(Table VI), and models included the propensity score. Patients who received a 19-mm prosthetic valve were at increased risk of prolonged intensive care unit stay (
72 hours) (OR 1.8; 95% CI 0.99, 3.4; P = .05). A small valve did not appear to confer risk of any other morbidity, although a number of morbidities, particularly adult respiratory distress syndrome and sepsis, occurred infrequently.
|
21-mm valves. Survival at 48 months after the operation was 85% ± 5% (n = 20) in patients who received 19-mm valves and 81% ± 4% (n = 43) in patients who received
21-mm valves. In the univariable proportional hazards model, 19-mm valve was not related to late death (hazard ratio 1.0; 95% CI 0.5, 2.0; P = .95). In the multivariable model that included a propensity score, there continued to be no difference in hazard of death between patients receiving 19-mm valves and those receiving
21-mm valves (hazard ratio 0.7; 95% CI 0.3; 1.8; P = .51). | Discussion |
|---|
|
|
|---|
No randomized studies have been done to answer the question whether a patient with a small aortic anulus is better treated by insertion of a 19-mm prosthetic valve or by root enlargement with insertion of a larger valve. Several recent studies have attempted to clarify the consequences of inserting a small prosthetic aortic valve. Unfortunately, many of these studies have included patients undergoing valve replacement for aortic insufficiency or patients undergoing concomitant mitral valve replacement,
5,28 which complicates comparisons of reported outcomes.
29 We limited our study to elderly patients with stenotic aortic disease with or without coronary artery disease in an attempt to identify a homogeneous cohort.
We were surprised to identify a significant increase in operative mortality among patients receiving a size 19-mm prosthetic valve. The selective impact of 19-mm valve insertion on operative mortality was elucidated only after we identified the subgroup at risk: elderly male patients with a measured 19-mm anulus. Medalion and associates
5 recently published their experience with insertion of small aortic valves in octogenarians and noted patients receiving 19-mm valves exhibited a trend toward a higher operative mortality, but they did not specifically address differences related to sex. The factors responsible for the poor outcome in our male subgroup remain unclear. Certainly size mismatch may have been an important variable given 7 of 9 men who received a 19-mm prosthesis had a BSA of 1.7 m2 or more. It should be noted that women with a BSA of 1.7 m2 or more who received a 19-mm valve were not at increased risk for mortality. It is also possible that the poor outcome observed in men did not result directly from the hemodynamic consequence of 19-mm valve insertion. The presence of a small anulus may be a marker for other undefined risk factors that may in a collective manner adversely affect outcome in men more than women. It is known, for example, that there are differences related to sex in left ventricular adaptation to aortic stenosis, and in general abnormal myocardial architecture and ventricular dysfunction are more commonly observed in men.
30 Furthermore, Morris and associates
4 demonstrated a positive independent effect of female sex on recovery of left ventricular ejection fraction after AVR. Recently, Cohen and colleagues
31 have also reported that male sex has a negative impact on late survival after bioprosthetic AVR. Our subgroup of men receiving 19-mm valves is too small to enable us to draw specific conclusions, but our observation of increased operative mortality warrants further investigation.
Although data regarding postoperative prosthetic transvalvular gradients and calculated effective valve orifice areas vary widely, the consensus is that patients surviving insertion of a small prosthetic valve are left with a fixed degree of left ventricular outflow tract obstruction. As a result, the regression of left ventricular hypertrophy is slower than in recipients of larger valves.
1,2,11 The impact of persistent prosthetic outflow obstruction on late survival is controversial and has been previously addressed by several investigators. Kratz and associates
3 reported that patients with a BSA of more than 1.9 m2 who received a 19-mm St Jude Medical aortic valve were more likely to experience late sudden death. He and colleagues
24 noted that patient-prosthesis size mismatch (
21-mm size prosthetic valve with BSA > 1.7) in the setting of concomitant CABG was a negative determinant for long-term survival. In contrast, Sawant and associates
8,9 found no correlation between insertion of a 19-mm St Jude Medical valve and BSA with late mortality. Similarly, Medalion and coworkers
5 found that long-term survival was unaffected by the combination of 19-mm prosthetic valve and BSA more than 1.7 m2. We did not observe a higher late mortality in our patients receiving 19-mm prostheses regardless of BSA, but our follow-up remains relatively short.
Our findings have caused us to think carefully about our use of standard 19-mm aortic prostheses in elderly men. Although the number of patients in this subgroup is extremely small (9/366 patients), it is hard to ignore their poor outcome. It would appear that a higher performance valve, such as a homograft or stentless valve, and/or root enlargement procedure should be considered in men with a measured 19-mm anulus. Ongoing trials with higher performance valves in elderly patients may identify other subgroups that would benefit from similar management.
| Appendix: Discussion |
|---|
|
|
|---|
What seems to have caught Dr Adams attention is an excessively high operative mortality of 16.7% when a 19-mm prosthesis was used to replace the stenotic aortic valve. This is 5 times higher than the 3% mortality when larger valves were used. The rate was 14% in women and even worse when a 19-mm valve was used in men: 4 of 9, or 44%, died. The authors conclude that insertion of a 19-mm prosthesis carries a substantial risk of death, especially in men, but also in women, and advised aortic root enlargement or perhaps the use of a stentless prosthesis.
I agree with this conclusion and would extend it a few more steps. We are presently using stentless porcine valve prostheses in nearly all patients over the age of 70 years because of superior hemodynamic performance. In situations in which mechanical prostheses are indicated, we do not use 19-mm valves at all and only use 21-mm prostheses in patients who have a BSA less than 1.5 m2 and who are sedentary. This is standard textbook policy.
In the original abstract, I noted that operative mortality was doubled in the 21-mm valves. Dr Adams, would you comment on how 21-mm valves should be used in practice?
Dr Adams. Thank you, Dr Doty. On the basis of our data, I would implant a 21-mm valve without hesitation, except perhaps in an extremely large patient. We did find a doubling of operative mortality with univariable analysis of 21-mm valves, but we later combined 21-mm and larger valves because there was little difference in their operative outcome once multiple variables were taken into account.
We are not ready to join you in abandoning the use of 19-mm valves, but we will be using fewer of them in elderly men. In general, stentless valve or root enlargement procedures are more tedious, and I think we will continue to perform the simplest operation possible in most patients. I believe the "standard" textbook policy" you referred to may need to be revised. Ongoing randomized studies comparing stentless and stented valves, particularly in the smaller valve size groups, should clarify optimal patient/valve matching.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J Mascherbauer, R Rosenhek, C Fuchs, E Pernicka, U Klaar, C Scholten, M Heger, G Wollenek, G Maurer, and H Baumgartner Moderate patient-prosthesis mismatch after valve replacement for severe aortic stenosis has no impact on short-term and long-term mortality Heart, December 1, 2008; 94(12): 1639 - 1645. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Mihaljevic, E. R. Nowicki, J. Rajeswaran, E. H. Blackstone, L. Lagazzi, J. Thomas, B. W. Lytle, and D. M. Cosgrove Survival after valve replacement for aortic stenosis: Implications for decision making. J. Thorac. Cardiovasc. Surg., June 1, 2008; 135(6): 1270 - 1279.e12. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Desai and G. T. Christakis Bioprosthetic Aortic Valve Replacement: Stented Pericardial and Porcine Valves Card. Surg. Adult, January 1, 2008; 3(2008): 857 - 894. [Full Text] |
||||
![]() |
T. Kunihara, K. Schmidt, P. Glombitza, V. Dzindzibadze, H. Lausberg, and H.-J. Schafers Root replacement using stentless valves in the small aortic root: a propensity score analysis. Ann. Thorac. Surg., October 1, 2006; 82(4): 1379 - 1384. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gilard, J.-C. Cornily, P.-Y. Pennec, C. Joret, G. Le Gal, J. Mansourati, J.-J. Blanc, and J. Boschat Accuracy of Multislice Computed Tomography in the Preoperative Assessment of Coronary Disease in Patients With Aortic Valve Stenosis J. Am. Coll. Cardiol., May 16, 2006; 47(10): 2020 - 2024. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. David Is Prosthesis-Patient Mismatch a Clinically Relevant Entity? Circulation, June 21, 2005; 111(24): 3186 - 3187. [Full Text] [PDF] |
||||
![]() |
W. Mistiaen, Ph. Van Cauwelaert, Ph. Muylaert, S. U. Sys, F. Harrisson, and H. Bortier Thromboembolic events after aortic valve replacement in elderly patients with a Carpentier-Edwards Perimount pericardial bioprosthesis J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1166 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Blackstone, D. M. Cosgrove, W.R. E. Jamieson, N. J. Birkmeyer, J. H. Lemmer Jr, D. C. Miller, E. G. Butchart, G. Rizzoli, M. Yacoub, and A. Chai Prosthesis size and long-term survival after aortic valve replacement J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 783 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Florath, U. P. Rosendahl, A. Mortasawi, S. F. Bauer, F. Dalladaku, I. C. Ennker, and J. C. Ennker Current determinants of operative mortality in 1400 patients requiring aortic valve replacement Ann. Thorac. Surg., July 1, 2003; 76(1): 75 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Freed, J. W. Tam, M. C. Moon, G. E.J. Harding, E. Ahmad, and E. A. Pascoe Nineteen-millimeter prosthetic aortic valves allow normalization of left ventricular mass in elderly women Ann. Thorac. Surg., December 1, 2002; 74(6): 2022 - 2025. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Willmann, D. Weishaupt, M. Lachat, R. Kobza, J. E. Roos, B. Seifert, T. F. Luscher, B. Marincek, and P. R. Hilfiker Electrocardiographically Gated Multi-Detector Row CT for Assessment of Valvular Morphology and Calcification in Aortic Stenosis Radiology, October 1, 2002; 225(1): 120 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Molina Enlargement of the aortic annulus using a double-patch technique: a safe and effective method Ann. Thorac. Surg., February 1, 2002; 73(2): 667 - 670. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |